GEISTWERT Rechtsanwälte Lawyers Avvocati

ORD_598583/2023

Sanofi Biotechnologies SAS, Regeneron Pharmaceuticals Inc. v. Amgen Inc. , Amgen GmbH, Amgen Europe B.V., Amgen NV, Amgen S.R.L., Amgen B.V., Amgen S.A.S.

Datum
2025-05-13
Kammer
Düsseldorf (DE) Local Division
Verfahrensart
Infringement Action
Sprache
EN

Metadaten

Fall-IDORD_598583-2023-d5cfde99ea74
Aktenzeichen
RegisterzeichenORD_598583/2023
EntscheidungsreferenzORD_598583/2023
Schlagwörter
Leitsätze

Dokumente und Volltext

Textextraktion: pypdf | Seiten: 42

1 Düsseldorf Local Division UPC_CFI_505/2024 Decision of the Court of First Instance of the Unified Patent Court delivered on 13 May 2025 concerning EP 3 536 712 B1 Headnotes: 1. In the case of a second medical use claim, a substance or composition within the mean- ing of Art. 54(4) EPC is used for any specific use which is not comprised in the state of the art. Such a therapeutic use can be a new indication, e.g. a disease not yet t reated by the claimed substance, or an indication for a new group of patients. 2. For a finding of infringement of a second medical use claim, the alleged infringer must offer or place the medical product on the market in such way that it leads or may lead to the claimed therapeutic use of which the alleged infringer knows or reasonably should have known that  ...